Q: What Is Rezon Bio And How Does It Differ From Polpharma Biologics?

Rezon Bio’s evolution reflects how a long-standing pharmaceutical foundation can be transformed into a specialized biologics CDMO platform. With roots extending back to Polpharma’s role in Polish pharmaceuticals since 1935, the company’s biologics capabilities began taking shape nearly 15 years ago through focused investment in biosimilar development, advanced manufacturing, and regulatory-grade quality systems. That foundation grew into deep expertise across analytical development, process development, clinical manufacturing, and commercial-scale GMP production, supported by successful FDA, EMA, and MHRA inspections.

Access the full Q&A to learn more.